This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Guven, G. S. Articles by Sözen, T. Search for Related Content PubMed PubMed Citation Articles by Guven, G. S. Articles by Sözen, T. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Obesity Social Bookmarking                         What's this?

Decrements in the Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Association with Orlistat Treatment in Obesity

Department of Internal Medicine, Section of General Internal Medicine, Hacettepe University Medical School, Ankara, Turkeygsain{at}tr.net

Alpaslan Kiliçaslan, MD

S. Gul Oz, MD

Department of Internal Medicine, Section of General Internal Medicine, Hacettepe University Medical School, Ankara, Turkey

Ibrahim C. Haznedaroglu, MD

Serafettin Kirazli

Department of Internal Medicine, Section of Hematology, Hacettepe University Medical School, Ankara, Turkey

Dilek Aslan, MD, MSc

Department of Internal Medicine, Department of Public Health, Hacettepe University Medical School, Ankara, Turkey

Tümay Sözen, MD

Department of Internal Medicine, Section of General Internal Medicine, Hacettepe University Medical School, Ankara, Turkey

Obesity and its associated metabolic complications can impair the physiologic regulation of fibrinolysis, leading to a hyper coagulable state. We aimed to assess circulating thrombin activatable fibrinolysis inhibitor (TAFI) levels in obese female patients and to test the effects of orlistat-induced weight loss on basal TAFI concentrations. Obese female outpatients age 18 and older, with a body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters) of at least 30, were included into the study. Thirteen nonobese (median BMI, 22.60 kg/m²) age-matched females were taken as controls. Plasma TAFI levels were measured before orlistat administration and after 6 months of orlistat treatment in the obese group and only one measurement was done in the control group. Twenty-seven obese patients were recruited into the study. The median TAFI level of the control group was 124.00; this value was significantly lower than the basal TAFI level of the obese group (p < 0.001). TAFI levels after orlistat therapy were statistically significantly lower than basal TAFI levels (p < 0.001) in the obese group. Hemostatic abnormalities including TAFI alterations represent a link between obesity and vascular thrombosis. Effective interventions should be considered in improving the obesity-associated prothrombotic risk profile.

Key Words: Obesity • Thrombosis • TAFI

Clinical and Applied Thrombosis/Hemostasis, Vol. 12, No. 3, 364-368 (2006)
DOI: 10.1177/1076029606291403


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?